Galantamine hydrobromide (marketed as Razadyne, formerly Reminyl) Information
FDA and other international health authorities are reviewing the safety of Razadyne after data from two clinical studies indicated that people taking the drug had a higher death rate than those taking a placebo (sugar pill). Based on this information, FDA has asked the manufacturer to revise the labeling. Please ask your healthcare provider if Razadyne is right for you.
This information reflects FDA’s preliminary analysis of data concerning this drug. FDA is considering, but has not reached a final conclusion about, this information. FDA intends to update this sheet when additional information or analyses become available.
Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this page.